Core Viewpoint - The pharmaceutical sector is experiencing a mixed performance in 2025, with a significant number of companies forecasting profit increases, while others are facing substantial losses. Group 1: Profit Forecasts - A total of 283 pharmaceutical stocks have disclosed their 2025 earnings forecasts, with 160 companies expecting year-on-year profit growth. Among these, Sino Medical has the highest projected increase, with an expected profit growth of over 32 times [1][4]. - WuXi AppTec is anticipated to achieve a record net profit of 19.15 billion yuan, marking the highest since its listing. This includes nearly 5.6 billion yuan in non-recurring gains from the sale of equity interests [6]. - Sino Medical's projected net profit for 2025 is between 43 million and 50 million yuan, reflecting a year-on-year increase of 2,767% to 3,233%. The growth is attributed to stable revenue from its neuro-interventional business and a 22% increase in its coronary intervention business due to the implementation of a national procurement policy [4][5]. Group 2: Loss Forecasts - Over 120 companies are forecasting profit declines for 2025, with 39 facing their first losses since going public, including companies like Zhifei Biological and Zhenbao Island. Zhifei is expected to report a loss of between 10.698 billion and 13.726 billion yuan, a decline of 630% to 780% compared to the previous year [2][8]. - Zhenbao Island anticipates a net loss of between 1.012 billion and 1.173 billion yuan, attributed to delays in the procurement process and increased cost control measures [8]. - Huiyu Pharmaceutical's losses are primarily due to non-core investment losses, with a fair value loss of 173 million yuan from its investment in Zhejiang Tongyuan Kang Pharmaceutical [9]. Group 3: Innovative Drug Companies - The innovative drug sector is showing signs of recovery, with companies like Nocera and Rongchang Biopharma expected to turn losses into profits. Nocera forecasts a net profit of approximately 633 million yuan, a significant increase from the previous year [3][11]. - Rongchang Biopharma is also expected to achieve profitability with projected revenues of around 3.25 billion yuan, a year-on-year increase of about 89% [11]. - Companies like Junshi Biosciences are reducing their losses significantly, with an expected net loss of around 873 million yuan, a reduction of 408 million yuan compared to the previous year [11][12].

截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 510,476,909 | RMB | | 1 | RMB | | 510,476,909 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 510,476,909 | RMB | | 1 | RMB | | 510,476,909 | | 2. 股份分類 | 普通股 | A 股份類別 | | | 於香港聯交所上市 (註1) | | 否 ...

| 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02359 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 510,476,909 | RMB | | 1 | RMB | | 510,476,909 | | 增加 / 減少 (-) | | | 0 | | | | RMB | | 0 | | 本月底結存 | | | 510,476,909 | RMB | | 1 | RMB | | 510,476,909 | 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 無錫藥明康德新藥開發股份有限公司 呈交日期: 2026年2月3日 I. 法定/註冊股本變動 | 2. 股份分類 ...

Core Insights - The global CXO industry is entering a new phase, with leading companies adopting a strategy to build a "diversified yet centralized" global network [1] - Due to geopolitical tensions and fluctuating tariff policies, global pharmaceutical outsourcing companies need to implement cross-regional diversification strategies to balance local and overseas production capacities [1] - WuXi AppTec's (药明康德) strategic deployment over the past few years aligns with this industry consensus, demonstrating its effectiveness through consistently exceeding performance expectations [1] Financial Performance - WuXi AppTec expects total revenue to reach 45.46 billion yuan in 2025, representing a year-on-year increase of 15.84%, with a 21.40% increase in revenue from continuing operations [1] - The adjusted Non-IFRS net profit attributable to the parent company is projected to be 14.96 billion yuan, reflecting a year-on-year growth of 41.3% [1] - The company is set to achieve record-high free cash flow in 2025, supported by capital expenditures of 5.5 to 6 billion yuan [3] Global Operations - WuXi AppTec has established a global operational system with over 20 R&D and production bases across Asia, Europe, and North America, serving approximately 6,000 clients [5] - The company is accelerating global capacity expansion to create a flexible and reliable global supply chain network, which will be crucial for capturing global market opportunities [5] Strategic Partnerships - In addition to consolidating traditional markets, WuXi AppTec has made strategic moves into emerging regions, signing memorandums of understanding with NEOM and the Saudi Ministry of Health [7] - These partnerships lay the groundwork for establishing a world-class CRDMO R&D and production base in NEOM and other areas in Saudi Arabia, marking a significant step in expanding its global network into the Middle East [7]

Group 1 - The core viewpoint of the news is that WuXi AppTec experienced a decline in stock price and trading volume, with significant financing activities indicating a mixed sentiment among investors [1][2]. Group 2 - On February 2, WuXi AppTec's stock fell by 2.10%, with a trading volume of 3.425 billion yuan. The financing buy-in amount was 207 million yuan, while the financing repayment was 314 million yuan, resulting in a net financing outflow of 107 million yuan [1]. - As of February 2, the total balance of margin trading for WuXi AppTec was 6.364 billion yuan, with the financing balance of 6.349 billion yuan accounting for 2.75% of the circulating market value, which is above the 70th percentile level over the past year [1]. - In terms of securities lending, on February 2, WuXi AppTec repaid 18,600 shares and sold 4,400 shares, with a selling amount of 410,100 yuan. The remaining securities lending volume was 151,700 shares, with a balance of 14.1344 million yuan, which is below the 20th percentile level over the past year [1]. Group 3 - WuXi AppTec, established on December 1, 2000, and listed on May 8, 2018, provides a comprehensive platform for the discovery, development, and production of small molecule chemical drugs, serving global pharmaceutical companies [2]. - The company's revenue composition includes 78.37% from chemical business, 12.93% from testing services, 6.02% from biological services, and 1.90% from other supplementary services [2]. - For the period from January to September 2025, WuXi AppTec achieved a revenue of 32.857 billion yuan, representing a year-on-year growth of 18.61%, and a net profit attributable to shareholders of 12.076 billion yuan, with a year-on-year increase of 84.84% [2]. Group 4 - Since its A-share listing, WuXi AppTec has distributed a total of 14.06 billion yuan in dividends, with 10.406 billion yuan distributed over the past three years [3]. - As of September 30, 2025, the top ten circulating shareholders of WuXi AppTec included Hong Kong Central Clearing Limited as the second-largest shareholder, holding 249 million shares, a decrease of 52.6071 million shares from the previous period [3]. - Other notable shareholders include Huaxia SSE 50 ETF and Huatai-PB CSI 300 ETF, which have also seen reductions in their holdings [3].

Core Viewpoint - The report highlights the premium rates of AH shares, with Northeast Electric (00042), Sinopec Oilfield Service (01033), and Zhejiang Shibao (01057) leading in premium rates, while CATL (03750), China Merchants Bank (03968), and Heng Rui Medicine (01276) are at the bottom of the list [1] Premium Rate Rankings - The top three AH shares by premium rate are: - Northeast Electric (00042) with a premium rate of 864.29% - Sinopec Oilfield Service (01033) with a premium rate of 361.80% - Zhejiang Shibao (01057) with a premium rate of 345.22% [1] - The bottom three AH shares by premium rate are: - CATL (03750) with a premium rate of -14.10% - China Merchants Bank (03968) with a premium rate of -4.16% - Heng Rui Medicine (01276) with a premium rate of 0.99% [1] Deviation Value Rankings - The top three AH shares by deviation value are: - Sinopec Oilfield Service (01033) with a deviation value of 89.71% - Northeast Electric (00042) with a deviation value of 34.53% - Zhongwei New Materials (02579) with a deviation value of 25.28% [1] - The bottom three AH shares by deviation value are: - Zhejiang Shibao (01057) with a deviation value of -53.92% - Changfei Optical Fiber (06869) with a deviation value of -35.50% - Nanhua Futures (02691) with a deviation value of -30.81% [1] Additional Insights - The report includes detailed tables showing the premium rates and deviation values for various AH shares, indicating significant disparities in market valuations between H-shares and A-shares [2]

Core Insights - The article discusses the tragic story of Zhao Ning, a prominent figure in the pharmaceutical industry, who despite her wealth and control over two publicly listed companies with a market value of 370 billion yuan, could not overcome her battle with cancer [1][2]. Company Overview - Zhao Ning co-founded WuXi AppTec and WuXi Biologics, which together hold a significant market value of 370 billion yuan and dominate the research and development landscape for top global pharmaceutical companies [1]. - The companies have played a crucial role in elevating China's pharmaceutical research capabilities to international standards, providing affordable medications to the public [12]. Industry Context - The narrative highlights the challenges faced by the pharmaceutical industry in China during the early 2000s, where there was a lack of domestic drug approval standards and a heavy reliance on imported medications [3][6]. - Zhao Ning and her partner made a strategic decision to pivot towards Contract Research Organization (CRO) services, allowing them to gain valuable insights and expertise from leading global pharmaceutical companies [7]. Personal Journey - Zhao Ning's personal struggle with cancer spanned 20 years, during which she managed to build a successful business while undergoing treatment [9]. - Despite her health challenges, she remained actively involved in the operations of her companies, demonstrating resilience and dedication to her work [9][10]. Legacy - Zhao Ning left behind a significant educational fund of 100 million yuan for her alma mater, Peking University, symbolizing her commitment to advancing education and research in the field [11]. - Her legacy is marked by the impact she had on the pharmaceutical industry in China, enabling many citizens to access life-saving medications, despite her inability to save herself [12].

Core Insights - The CDMO (Contract Development and Manufacturing Organization) business of multinational companies in China is experiencing significant decline, with many exiting the market entirely [1][8] - The Chinese CDMO market is growing rapidly, with a compound annual growth rate of 39.9% from 2018 to 2023, and is expected to reach 208.4 billion RMB by 2028 [16] Group 1: Multinational CDMO Operations in China - Multinational companies like Lonza, Thermo Fisher, and Merck have faced challenges in their CDMO operations in China, with many either closing facilities or selling them off [4][5][6] - Lonza's Guangzhou factory, which was operational for only three years, was sold to a local company due to insufficient orders [4] - Thermo Fisher's factory in Hangzhou is struggling with low order volumes, and its future remains uncertain [5][6] Group 2: Local CDMO Developments - Zhaoyan Biotech's new manufacturing base in Guangzhou, which focuses on large molecule CDMO, signifies a strategic move to enhance capacity and create a collaborative platform for biopharmaceutical innovation in Southeast Asia [3] - Local companies are increasingly building their own production capabilities, reducing reliance on foreign CDMO services [14] Group 3: Market Dynamics and Trends - The introduction of the MAH (Marketing Authorization Holder) system in 2019 has lowered production barriers, allowing more companies to utilize CDMO services [11] - Despite the advantages of a large workforce and lower costs, foreign CDMOs have struggled to establish a foothold in China due to high pricing models that do not align with local market conditions [12][13] - The efficiency and cost-effectiveness of Chinese CDMOs are becoming competitive with their foreign counterparts, leading to a shift in market dynamics [15][16]

Core Viewpoint - The fourth quarter of 2025 saw increased market volatility, with A-shares and Hong Kong stocks ending the year amidst structural market trends. Major indices showed mixed performance, while sectors like AI computing and semiconductors thrived, contrasting with weaker performances in real estate, pharmaceuticals, and computing [1][2]. Group 1: Performance of Funds - Star fund managers like Fu Pengbo and Li Xiaoxing achieved significant excess returns in 2025, with their funds rising over 60% for the year, primarily due to heavy investments in AI computing and semiconductors [1]. - Balanced funds, such as Zhu Shaoxing's, demonstrated stable performance with a yearly increase of over 20%, benefiting from diversified holdings across various sectors [2][11]. - Traditional value-focused funds faced considerable net value pressure, with notable losses in the fourth quarter, particularly in sectors like consumption and pharmaceuticals [2][10]. Group 2: Investment Strategies - Funds focusing on technology growth, such as Fu Pengbo's and Li Xiaoxing's, increased allocations to data center cooling and semiconductor-related companies, reflecting a shift in their top holdings [5][6]. - Zhu Shaoxing's balanced approach, which included investments in banking and consumer sectors, effectively mitigated market volatility, leading to a net value increase [11]. - Fund managers emphasized the importance of stock selection in a concentrated market, with a focus on companies with core technological advantages and strong performance metrics [16]. Group 3: Sector Insights - The technology sector, particularly AI and semiconductors, remains a key focus for fund managers, with expectations of continued growth driven by domestic advancements [6][12]. - The pharmaceutical sector is undergoing positive changes, with improved policy environments and innovation capabilities, although some funds still faced challenges due to market adjustments [9][10]. - The consumer market is viewed positively, with strong domestic demand expected to support technological innovation and economic growth [8][10].

Core Insights - The pharmaceutical industry is increasingly adopting AI technologies, with over 60% of pharmaceutical companies and more than half of public hospitals using DingTalk as an AI operating system to enhance productivity [1][2] - AI is transforming the pharmaceutical sector by enabling companies to shift from repetitive tasks to more strategic roles, thereby enhancing operational efficiency [1][2] - DingTalk's AI application white paper indicates that AI is moving from exploration to large-scale application across the pharmaceutical value chain, impacting drug discovery, production, quality control, and patient services [1][2] Industry Developments - The pharmaceutical industry is characterized by high specialization, strong regulation, and long supply chains, making AI implementation a systemic transformation rather than just a technological upgrade [2] - DingTalk's AI solutions have been successfully implemented in various pharmaceutical companies, including WuXi AppTec and Innovent Biologics, and the company plans to launch a "Digital Pioneer Competition" to cultivate AI-savvy individuals within 100 pharmaceutical firms [2][3] - The establishment of the "Pharmaceutical Industry AI Innovation Alliance" aims to address common challenges such as data governance and ethical standards, promoting best practices for AI development in the sector [2][3] Company Case Studies - WuXi AppTec and DingTalk have developed a digital foundation called "BaiYaoDing," integrating AI into various processes, including traditional Chinese medicine traceability and smart factory production [2][3] - Innovent Biologics focuses on fine management in production through AI, achieving digitalization and transparency in anomaly handling, which has led to significant labor savings and improved quality [3] - Lepu Medical's AI initiatives provide 24/7 professional knowledge support to sales teams, resulting in a 200% return on AI investment by 2025, demonstrating AI's direct value in driving business growth [3] - Xianle Health has utilized AI tools to create an intelligent inspection application, enhancing management efficiency and fostering a culture of innovation within the organization [3][4] Future Outlook - AI is becoming a core driver of quality improvement, efficiency, and innovation in the pharmaceutical industry, with ongoing advancements in technology and a thriving ecosystem [4]